The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Apr 5, 2020 • 38min
Ep66: Mike Pellini
In this conversation, Mike Pellini, managing partner at Section 32 and former CEO of Foundation Medicine, dives deep into the world of diagnostic testing, particularly during the COVID-19 pandemic. He critiques the federal testing failures and discusses the need for a cohesive national framework. Pellini emphasizes the critical yet overlooked role of diagnostic testing in healthcare decision-making and advocates for better recognition and funding. He also highlights logistical challenges and the importance of data aggregation in enhancing public health management.
Mar 24, 2020 • 58min
Ep65: Alexis Borisy & Melanie Nallicheri
Leaders of EQRx, a company aspiring to make novel drugs at low prices.
Mar 9, 2020 • 49min
Ep64: Isabella de la Houssaye
Isabella is a Stage 4 lung cancer patient on a mission.
Feb 25, 2020 • 59min
Ep63: Jeremy Levin
Jeremy Levin, chairman of BIO, on the perilous moment in politics.
Feb 11, 2020 • 56min
Ep62: Jane Grogan
Jane Grogan, CSO of Arsenal Bio, on programmable cell therapies.
Jan 27, 2020 • 1h 5min
Ep61: Sanjiv Patel
Sanjiv Patel, CEO of Relay Therapeutics, computational drug discovery company.
Jan 14, 2020 • 1h 10min
Ep60: Tim Mayleben
Tim Mayleben, CEO of Esperion Therapeutics, on cholesterol-lowering meds.
Dec 30, 2019 • 1h 2min
Ep59: David Baker
David Baker, University of Washington protein designer.
Dec 3, 2019 • 1h 12min
Ep58: Jigar Raythatha
Jigar Raythatha of Constellation Pharma on epigenetic drug development.
Nov 26, 2019 • 1h 21min
Ep57: John Alam
John Alam on Alzheimer's drug development.
